BioSpace News Archive

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Biomea Fusion, Inc. today announced that it will host a conference call and webcast to discuss the initial clinical data from the first two cohorts of the Phase II portion of COVALENT-111 on Tuesday, March 28th at 8:30 am ET.

Jasper Therapeutics, Inc. today announced the appointment of Daniel Adelman, M.D., as the company’s Acting Chief Medical Officer.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present two posters at the upcoming International Society of Nephrology’s World Congress of Nephrology (WCN) 2023 meeting taking place in Bangkok, Thailand from March 30 – April 2, 2023.

EVERSANA® announced a partnership with ChemoMouthpiece, LLC to support the launch and commercialization of its medical device, the Chemo Mouthpiece™, to assist oncology patients across the United States.

AnPac Bio-Medical Science Co., Ltd. announced that on March 22, 2023, the Company has been notified by the Nasdaq Hearings Panel (“Panel”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s request for continued listing on The Capital Market has been granted.

JanOne today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 361,000 shares of the Company’s common stock at a purchase price of $1.

IMUNON, Inc. announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 30, 2023 to discuss financial results for the fourth quarter and full year ended December 31, 2022 and provide an update on its clinical development of IMNN-001.

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.

Evoke Pharma, Inc. and EVERSANA Life Science Service LLC announced a summary of real-world data on the positive impact of GIMOTI usage in decreasing the utilization of healthcare resources by patients with diabetic gastroparesis.